A Phase I, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects
Latest Information Update: 15 Apr 2022
At a glance
- Drugs AR 09 (Primary)
- Indications Anaesthesia
- Focus Adverse reactions
- Sponsors Arbor Pharmaceuticals
- 22 Apr 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 Jan 2014 New trial record